"Targeting the ""untargetable"" by merging biological and chemical compound libraries"
Sector: Hospital • Location: Switzerland
Source: EU Funding & Tenders Portal
"Genome sequencing combined with powerful new research technologies has greatly expanded the number of potential drug targets, offering enormous opportunities to address unmet medical needs. However, for proteins with flat, featureless surfaces or for protein-protein interactions, it has been difficult to impossible to generate ligands based on classical small molecules, hindering their evaluation
- Status
- Under Construction
- Sector
- Hospital, Commercial, Chemical (Industrial), Manufacturing (Industrial), Education
- Location
- Switzerland
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about "Targeting the ""untargetable"" by merging biological and chemical compound libraries"
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | "Genome sequencing combined with powerful new research technologies has greatly expanded the number of potential drug targets, offering enormous opportunities to address unmet medical needs. However, for proteins with flat, featureless surfaces or for protein-protein interactions, it has been difficult to impossible to generate ligands based on classical small molecules, hindering their evaluation as targets and the development of drugs. Herein, we propose a new method and its application for targeting the so-called ""undruggable"" proteins by tapping into a new chemical space, generated by ""merging"" biological and chemical compound libraries. In brief, millions of short cyclic peptides (4–6 amino acids) genetically encoded by phage display (generated with methods we established previously) will be expanded by combinatorially attaching via lateral groups > 1000 different chemical fragments in separate wells of microwell plates. We will develop a strategy that combines the elements of i) automation, ii) liquid transfer by acoustic dispensing, iii) single-round phage display panning, iv) ""phage PCR"" and a primer coding strategy, v) next-generation sequencing (NGS) and vi) computational sequence analysis to perform phage display selections with a library comprising > 1000 non-natural building blocks. We expect that this technology will deliver ligands to challenging proteins and facilitate their evaluation as drug targets. The ligands are kept small on purpose, below one kDa, and the polarity is limited so that they are more likely to be cell permeable and so they may directly serve as leads for the generation of oral drugs. " |
Location
Country | Switzerland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Commercial, Chemical (Industrial), Manufacturing (Industrial), Education |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Switzerland
- SUN2CHEM
- BIOVERSYS (COVID-19) (IDFF)
- Helsinn New Cytotoxic Plant, Biasca
- Merck Biotech Development Facility, Corsier-sur-Vevey, Switzerland
- Thermo Fisher Scientific’s Biologics Manufacturing Facility, Lengnau, Switzerland
- AGORA Cancer Centre, Lausanne
- Personalised medical platform for patients with autoimmune diseases
- Acute care for addicts (ASBO)
